Patents Assigned to Dharmacon, Inc.
  • Patent number: 9988625
    Abstract: The present invention is directed to collections of templates for molecules such as RNA, as well as templates, devices, kits and methods for generating molecules from these collections. Through the use of various embodiments of the present invention one may efficiently and effectively obtain selected RNA molecules such as siRNA, shRNA, miRNA mimics and inhibitors, lncRNA, antisense RNA, aptamers, ribozymes, and sgRNA and sets of those molecules.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: June 5, 2018
    Assignee: Dharmacon, Inc.
    Inventors: Devin Leake, Annaleen Vermeulen, Brady Culver, Abel Licon, Joshua A. Stahl
  • Patent number: 9481895
    Abstract: Methods and kits for lentiviral production are provided. By separating certain components of the vector including but not limited to promoter, reporter and selection marker preference components from the genetic content of interest, one can create libraries that allow for the efficient generation of custom selected lentiviral vectors.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 1, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Jamie Cearley, Rusla DuBreuil
  • Patent number: 9382534
    Abstract: Lentiviral vectors, plates, kits and methods are provided that permit improved efficiency for selection of a promoter sequence for use in a lentiviral application. Through various embodiments of the present invention, a researcher may first evaluate and then choose in a modular fashion, a vector comprising a promoter that is effective for expression in a particular cell line or type.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: July 5, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventor: John Wakefield
  • Patent number: 9353368
    Abstract: The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The present disclosure also provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from an endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand designed t be at least partially complementary to a target RNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: May 31, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
  • Patent number: 9284552
    Abstract: The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: March 15, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Katie Jansen Spayd, Jon Karpilow, John K. Wakefield
  • Patent number: 9284554
    Abstract: The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The present disclosure also provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from an endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand designed to be at least partially complementary to a target RNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 15, 2016
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
  • Patent number: 8980855
    Abstract: Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are substantially complementary to one or more mature miRNAs or piRNAs.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: March 17, 2015
    Assignees: Elitech Holding B.V., GE Healthcare Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Annaleen Vermeulen, Rob Kaiser, Jon Karpilow, Nicolaas M. J. Vermeulen, Walt Mahoney
  • Patent number: 8841267
    Abstract: The present disclosure provides non-naturally occurring miR-196a-2 miRNAs and non-naturally occurring miR-204 miRNAs. The non-naturally occurring miRNAs of the disclosure have mature strand sequences distinct from their endogenous counterparts. The disclosure also provides methods of selecting mature strand sequences that function optimally in non-naturally occurring miR-196a-2 miRNAs. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: September 23, 2014
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Melissa Kelley, Amanda Birmingham, Jon Karpilow, Anastasia Khvorova, Kevin Sullivan
  • Patent number: 8809514
    Abstract: Provided herein are tripartite oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene. The tripartite oligonucleotide complexes of the disclosure may include a conjugate moiety that facilitates delivery to a cell, tissue or organism without the aid of a transfection reagent.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: August 19, 2014
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventors: Christina Yamada, Anastasia Khvorova, Rob Kaiser, Emily Anderson, Devin Leake
  • Publication number: 20140228251
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Application
    Filed: February 12, 2013
    Publication date: August 14, 2014
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8759508
    Abstract: The compounds are of class of chromophoric 1,2,3-triazolyl equipped silyl linking groups that are useful in the chemical synthesis of RNA.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: June 24, 2014
    Assignee: GE Healthcare Dharmacon, Inc.
    Inventor: Michael Oren Delaney
  • Publication number: 20130225447
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Application
    Filed: April 22, 2013
    Publication date: August 29, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Publication number: 20130225667
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Application
    Filed: April 22, 2013
    Publication date: August 29, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Publication number: 20130217121
    Abstract: The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 22, 2013
    Applicant: DHARMACON, INC.
    Inventors: Katie Jansen Spayd, Jon Karpilow, John K. Wakefield
  • Publication number: 20130210676
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.
    Type: Application
    Filed: March 20, 2013
    Publication date: August 15, 2013
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8501706
    Abstract: Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: August 6, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Christina Yamada, Anastasia Khvorova, Rob Kaiser, Emily Anderson, Devin Leake
  • Patent number: 8461326
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 11, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8445667
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 21, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8445668
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: May 21, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Patent number: 8426579
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: April 23, 2013
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe